The spatial and temporal genomic heterogeneity of various tumor types and advances in
technology have stimulated the development of circulating tumor DNA (ctDNA) genotyping …

Most solid tumors, including colorectal cancers, shed cell-free DNA (ctDNA) in the blood.
ctDNA can be analyzed to generate molecular profiles which capture the heterogeneity of …

The impact of ctDNA changes after chemotherapy on the clinical outcomes of patients with
metastatic colorectal cancer (mCRC) remains unclear. The present study evaluated the …

Purpose: ctDNA offers a promising, noninvasive approach to monitor therapeutic efficacy in
real-time. We explored whether the quantitative percent change in ctDNA early after therapy …

The importance of circulating free DNA (cfDNA) in cancer clinical research was recognized
in 1994 when a mutated RAS gene fragment was detected in a patient's blood sample. Up to …

Cancer is a common cause of death worldwide. Despite significant advances in cancer
treatments, the morbidity and mortality are still enormous. Tumor heterogeneity, especially …

Comprehensive genomic profiling enables genomic biomarker detection in advanced solid
tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we …

The application of circulating tumor DNA (ctDNA) represents a non-invasive method for
tumor detection. Its prognostic significance in patients with colorectal cancer is controversial …